time re-r liberti bell solid outlook
earn ag execut drive share higher
view make impress stride solidifi within
alongsid bayer syngenta basf dowdupont post larg round
ag consolid better disclosur surround geograph crop
market share realist lt target improv transpar
pipelin option margin sustain reason investor
re-visit stori doubl rate cash convers
mid-point first glanc appear aggress view
achiev given low capital-expenditure requir new buy-back
program establish dividend pay-out polici target
gross leverag clear attempt normal vs ag
specialti chemic peer key capit alloc thesi
see believ investor reluct give full credit cash
convers often cite one key reason histor critic
better confid revenu growth ag margin offer upsid
broad portfolio healthi ai pipelin drive manag
optim come year simpli rynaxypyr cyazypyr although
certainli help greater appreci lt pipelin
believ take addit stride toward better portfolio balanc
ad new fungicid product sweet spot still
revenu margin front believ leverag
improv product mix roll-off tsa singl sourc sap ad
new fungicid caus enthusiasm render ag segment margin
rang excl corp cost respect
adjust estimate preliminari guidanc lt target
rais ep estimate tp rise
higher sale growth lower share count risk ai inflat fx
competit landscap evolut lack execut cash gener
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
diversifi chemic compani serv
agricultur consum industri market solut
applic product oper busi segment
agricultur product specialti chemic industri
price dec rate outperform target price analyst christoph parkinson
profit tax
chang work capit
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
price driven greater expect top-
line growth margin improv ag solut assum
multipl ag solut market price
scenario
grey price driven weaker expect growth
margin ag solut along wors expect delay
ramp lithium carbon tonn suppli
nemaska assum multipl ag solut
market price scenario
top theme drive stori
follow comment new kid block investor day theme assess
key topic analyst day address investor sentiment across cpc space
increment new guidanc revenu growth compound-annual-growth-rate cpc
market growth ii organ growth fx headwind growth
cs view remain comfort view outperform broader cpc market
pt back rynaxypyr cyazypyr growth well ramp
 pipelin silver bullet fulli allevi patent expiri risk
onward list patent volum success incl author help
nonetheless investor still reserv concern regard price margin better
disclosur pipelin address market target geograph crop
market share target formul capabl offer investor confid under-
increment new guidanc ebitda compound-annual-growth-rate ii
margin improv gross margin sg leverag stabl sale
cs view given current chines ai procur headwind uncertainti view margin
guidanc realist view product mix manufactur improv eventu
re-balanc fungicid intermedi term margin tailwind follow tsa
roll benefit cse realiz regard mix benefit
current retain rynaxypyr cyazypyr believ new formul
moa ii like higher volum vs potenti price headwind iii geograph
breadth distribut depth offer power tool combat potenti price degrad
howev stress theme onward patent expiri
stagger geograph repres cliff contrari bear argument
view lt ag segment margin sustain rang
increment new guidanc increas annual dividend
set new target pay-out ratio ii new buy-back author
complet iii potenti increment capit return
beyond previous mention dividend increas share repurchas program
cs view perspect capit alloc integr new stori given
histor rel weak part bull thesi believ
intermedi long term outlook stark contrast past year although
fulli acknowledg take time investor embrac theme
show-m stori see impend inflect free cash flow gener
time attract new investor view defin buy-back program
dividend polici enough hold investor meantim
cs view difficult predict product balanc target
convinc want greater exposur fungicid better posit global
total solut provid current portfolio fungicid vs cpc industri
stress effort re-bal may entail molecul trade addit
gener cash consider consist exist thesi view larg
 probabl nt host factor primarili regulatori risk europ
lt view sumitomo potenti korean chemic player compat
platform view deal probabl next year
compani mention price
